Showing papers by "Henry R. Black published in 2010"

Heart Rate Response to Exercise Stress Testing in Asymptomatic Women The St. James Women Take Heart Project

Abstract: Background— The definition of a normal heart rate (HR) response to exercise stress testing in women is poorly understood, given that most studies describing a normative response were predominately based on male data. Measures of an attenuated HR response (chronotropic incompetence) and age-predicted HR have not been validated in asymptomatic women. We investigated the association between HR response to exercise testing and age with prognosis in 5437 asymptomatic women. Methods and Results— Participants underwent a symptom-limited maximal stress test in 1992. HR reserve (change in HR from rest to peak), chronotropic index, and age-predicted peak HR were calculated. Deaths were identified to December 31, 2008. Mean age at baseline was 52±11 years, with 549 deaths (10%) over 15.9±2.2 years. Mean peak HR was inversely associated with age; mean peak HR=206–0.88(age). After adjusting for exercise capacity and traditional cardiac risk factors, risk of death was reduced by 3% for every 1–beat-per-minute increase ...

Single-pill combination of telmisartan 80 mg/amlodipine 10 mg provides superior blood pressure reductions in patients with severe hypertension: teamsta severe htn study: ht.1.04

Abstract: Purpose: Investigate the efficacy and safety of the single-pill combination of telmisartan 80 mg/amlodipine 10 mg (T80/A10) vs. its respective monotherapy components in patients with severe hypertension. Methods: An 8-week, double-blind, parallel-group study, in 858 patients aged ≥18 years with severe hypertension (i.e. SBP ≥180 and DBP ≥95 mmHg) randomized to T80/A10 (n = 421) or to monotherapy with T80 (n = 217) or A10 (n = 220). The primary endpoint was change from baseline in seated trough cuff SBP. Results: Baseline characteristics were comparable between the treatment groups. At 8 weeks, significantly greater reductions from baseline in seated trough SBP/DBP were observed with T80/A10 vs. T80 or A10 monotherapy, with superior reductions evident at 1 week. BP control and response rates were consistently higher with T80/A10 vs. T80 or A10 alone. T80/A10 was well tolerated, with similar rates of common adverse events (AEs) vs. T80 or A10 monotherapy. Treatment-related AEs were less frequent with T80/A10 (12.6%) vs. A10 (16.4%), with a numerically lower incidence of peripheral edema and rate of treatment discontinuation. Figure 1. No caption available. Conclusions: Treatment of severe hypertensive patients with a single-pill combination containing T80/A10 results in significantly greater BP reductions (-47.5/-18.7 mmHg) and higher BP control/response rates than the respective monotherapies. The safety profile of T80/A10 single-pill combination is comparable to that of its respective components.